Chemo-hormonal therapy for Metastatic Hormone-sensitive Prostate Cancer: Clinical Trial Fantasy or Practice Reality?This paper deals with the occurrence frequency of debris flow hazard in the areas lack of the
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; ...
Metastatic hormone-sensitive prostate cancer (mHSPC) is deadly, with a reported median survival of less than 5 years. Historically, androgen deprivation therapy (ADT) has been the standard of care. The development of new therapeutic options, however, has significantly improved survival. In this ReCA...
Metastatic prostate cancer is considered to be incurable. But now a pilot trial, in 20 selected men with early-stage metastatic prostate cancer, has shown that aggressive multimodality treatment with hormone therapy, surgery, and radiation "can eliminate detectable disease." Overall, 20% of the pat...
Various treatment options are available for metastatic hormone-sensitive prostate cancer. This study aimed to quantify how men with prostate cancer in the
Hormone Therapy Kidney Cancer Kidney StonesKidney StonesKidney StonesKidney StonesKidney StonesKidney Stones Men's Health Next-Generation Imaging OAB and IncontinenceOAB and Incontinence Pediatrics Prostate CancerProstate CancerProstate Cancer Sexual Dysfunction UTUC Urologic SurgeryUrologic Surgery Spotlight Busines...
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial Tanya B. Dorff, M. Suzette Blanchard, Lauren N. Adkins, Laura Luebbert, Neena Leggett, Stephanie N. Shishido, Alan Macias, Marissa M. Del Real, Gaurav Dhapola, Colt Egelston, John ...
prostate cancer becomes resistant to treatment when patients fail to respond to hormone therapy, radiation, andmultiplerounds of untargeted chemotherapy. in certain cases, these maximum therapeutic doses of untargeted chemoinundate thecancer cells, triggering their ability to pump out some of the anti-...
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30:1992–2003. Article CAS PubMed PubMed Central Google Scholar Fizazi K, Tran N, Fein L, Matsubara N, ...
In this report, we looked at two hormone therapy approaches for prostate cancer that is still sensitive to castration: one with treatment breaks and one without. Patients may tolerate therapy with breaks more easily, but this effect is not sustained and is not associated with better longevity. ...